LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

12.42 0.81

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

12.16

Max

12.5

Galvenie mērījumi

By Trading Economics

Ienākumi

1.4M

676K

Pārdošana

961K

18M

Dividenžu ienesīgums

0.48

Peļņas marža

3.67

Darbinieki

212

EBITDA

-3M

2.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+54.1% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.40%

Nākamie ieņēmumi

2026. g. 2. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-118M

250M

Iepriekšējā atvēršanas cena

11.61

Iepriekšējā slēgšanas cena

12.42

Ziņu noskaņojums

By Acuity

50%

50%

154 / 351 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. marts 19:08 UTC

Galvenie ziņu notikumi

TotalEnergies Shutting Production in Qatar, Iraq Amid Fighting in Middle East

2026. g. 13. marts 18:48 UTC

Peļņas
Galvenie tirgus virzītāji

Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss

2026. g. 13. marts 17:10 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

2026. g. 13. marts 17:10 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: Central Bank Decisions -2-

2026. g. 13. marts 16:47 UTC

Galvenie ziņu notikumi

The Week in Oil: Hormuz Crisis Pushes Brent Above $100

2026. g. 13. marts 22:27 UTC

Tirgus saruna
Galvenie ziņu notikumi

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

2026. g. 13. marts 22:13 UTC

Tirgus saruna
Galvenie ziņu notikumi

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

2026. g. 13. marts 22:04 UTC

Tirgus saruna
Galvenie ziņu notikumi

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

2026. g. 13. marts 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

2026. g. 13. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 13. marts 20:50 UTC

Tirgus saruna
Galvenie ziņu notikumi

Financial Services Roundup: Market Talk

2026. g. 13. marts 20:02 UTC

Tirgus saruna

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

2026. g. 13. marts 19:50 UTC

Tirgus saruna
Galvenie ziņu notikumi

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

2026. g. 13. marts 19:35 UTC

Galvenie ziņu notikumi

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

2026. g. 13. marts 19:00 UTC

Tirgus saruna

U.S. Natural Gas Futures Settle Lower -- Market Talk

2026. g. 13. marts 18:49 UTC

Galvenie ziņu notikumi

The Iran War Could Upend AI. Here's How. -- Barrons.com

2026. g. 13. marts 18:24 UTC

Galvenie ziņu notikumi

Impact of Middle East Conflict on TotalEnergies Activities

2026. g. 13. marts 18:00 UTC

Galvenie ziņu notikumi

Is War Good For the Economy? -- WSJ

2026. g. 13. marts 17:23 UTC

Tirgus saruna

U.S. Oil Rig Count Rises by 1 to 412 -- Market Talk

2026. g. 13. marts 16:46 UTC

Tirgus saruna
Galvenie ziņu notikumi

European Indexes End Week Lower as Oil Takes Driving Seat -- Market Talk

2026. g. 13. marts 16:38 UTC

Galvenie ziņu notikumi

Higher Oil Prices Could Bring a Global Economic Shock. This Is the Number to Watch. -- Barrons.com

2026. g. 13. marts 16:34 UTC

Iegādes, apvienošanās, pārņemšana

EQT Says It Received Around CHF21 Bln in Total From Galderma Share Sales

2026. g. 13. marts 16:33 UTC

Iegādes, apvienošanās, pārņemšana

EQT Receives Proceeds of Around CHF1.3B From Sell-Down

2026. g. 13. marts 16:32 UTC

Iegādes, apvienošanās, pārņemšana

EQT Completes Exit From Galderma

2026. g. 13. marts 16:20 UTC

Tirgus saruna
Galvenie ziņu notikumi

Financial Services Roundup: Market Talk

2026. g. 13. marts 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 13. marts 16:15 UTC

Galvenie ziņu notikumi

Why Exxon and Energy Stocks Finally Started to Rise This Week as the Iran War Escalated -- Barrons.com

2026. g. 13. marts 16:11 UTC

Tirgus saruna

Carney Tries to Put Dismal Canada Jobs Data in Context -- Market Talk

2026. g. 13. marts 16:00 UTC

Galvenie ziņu notikumi

Here's Where the U.S. Economy Is Most Vulnerable to Iran War -- WSJ

2026. g. 13. marts 15:48 UTC

Tirgus saruna
Galvenie ziņu notikumi

Oil Futures Turn Higher as Supply Worries Remain -- Market Talk

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

54.1% augšup

Prognoze 12 mēnešiem

Vidējais 19 USD  54.1%

Augstākais 19 USD

Zemākais 19 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

2

Pirkt

2

Turēt

0

Pārdot

Noskaņojums

By Acuity

154 / 351 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat